---
title: "15:47 ETImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286958486.md"
description: "Investors who suffered losses in ImmunityBio, Inc. (NASDAQ: IBRX) have the opportunity to lead a securities fraud class action lawsuit. The complaint alleges that the company misled investors about Anktiva's capabilities between January 19, 2026, and March 24, 2026. Interested parties must act before May 26, 2026, to participate."
datetime: "2026-05-19T19:47:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286958486.md)
  - [en](https://longbridge.com/en/news/286958486.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286958486.md)
---

# 15:47 ETImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

, /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) have opportunity to lead the securities fraud class action lawsuit.

**IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CLICK** **HERE** **BEFORE MAY 26, 2026 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.**

**What Is The Lawsuit About?**  
The complaint filed alleges that, between January 19, 2026 and March 24, 2026, Defendants failed to disclose to investors that: (1) Defendant Soon-Shiong materially overstated Anktiva's capabilities; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

**Contact Us To Participate or Learn More:  
**If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.  
The Law Offices of Frank R. Cruz,  
Email us at: \[email protected\]  
Call us at: 310-914-5007  
Visit our website at: www.frankcruzlaw.com  
Follow us for updates on Twitter: twitter.com/FRC\_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

### Related Stocks

- [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory](https://longbridge.com/en/news/286821171.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)